These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17319112)

  • 1. Blood pressure and control of cardiovascular risk.
    Whitworth JA
    Vasc Health Risk Manag; 2005; 1(3):257-60. PubMed ID: 17319112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some thoughts about recent hypertension trials.
    Conti CR
    Clin Cardiol; 2007 Jun; 30(6):268-70. PubMed ID: 17551957
    [No Abstract]   [Full Text] [Related]  

  • 3. [New treatment strategies for hypertension. Which guidelines and how to apply them].
    Blacher J; Baes M; Marchal A; Younes W; Legedz L; Safar M
    Presse Med; 2005 Oct; 34(18):1279-85. PubMed ID: 16269990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual influenza immunization: as important as control of blood pressure and cholesterol as secondary prevention for cardiovascular disease.
    Grajewski J; Slusar M; Hayney MS
    J Am Pharm Assoc (2003); 2007; 47(5):662-3. PubMed ID: 17848356
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria.
    Cuspidi C; Meani S; Salerno M; Severgnini B; Fusi V; Valerio C; Catini E; Magrini F; Zanchetti A
    Blood Press; 2004; 13(3):144-51. PubMed ID: 15223722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention.
    Karmali KN; Lloyd-Jones DM
    Hypertension; 2017 Mar; 69(3):e2-e9. PubMed ID: 28115516
    [No Abstract]   [Full Text] [Related]  

  • 7. Current role of beta-blockers in the treatment of hypertension.
    Aronow WS
    Expert Opin Pharmacother; 2010 Nov; 11(16):2599-607. PubMed ID: 20426702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):146-8. PubMed ID: 17679828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.
    Mourad JJ
    Vasc Health Risk Manag; 2008; 4(6):1315-25. PubMed ID: 19337545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive therapy and de-stiffening of the arteries.
    Safar ME; Jankowski P
    Expert Opin Pharmacother; 2010 Nov; 11(16):2625-34. PubMed ID: 20977399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.
    Abraham I; MacDonald K; Hermans C; Aerts A; Lee C; Brié H; Vancayzeele S
    Vasc Health Risk Manag; 2011; 7():209-35. PubMed ID: 21490947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of home blood pressure and ambulatory blood pressure monitoring in decisions of when and whom to treat: recommendations for practicing clinicians.
    Ogedegbe G
    J Cardiometab Syndr; 2006; 1(3):222-4. PubMed ID: 17679827
    [No Abstract]   [Full Text] [Related]  

  • 13. [New guidelines 2007 for the management of arterial hypertension].
    Krzesinski JM; Xhignesse P
    Rev Med Liege; 2007 Sep; 62(9):566-74. PubMed ID: 17966793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are guidelines effectively guiding antihypertensive therapy?
    Vasan RS; Kannel WB
    Am J Cardiol; 2007 Jul; 100(1):143-4. PubMed ID: 17599457
    [No Abstract]   [Full Text] [Related]  

  • 15. Can the effectiveness of hypertension management be improved?
    Ruilope LM
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):689-95. PubMed ID: 23750678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium.
    Fagard RH; Van Den Enden M; Leeman M; Warling X
    J Hypertens; 2002 Jul; 20(7):1297-302. PubMed ID: 12131525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines 2007 of the European Societies of Hypertension and of Cardiology: what has changed?].
    Schmieder RE
    Dtsch Med Wochenschr; 2007 Nov; 132(46):2463-6. PubMed ID: 17987556
    [No Abstract]   [Full Text] [Related]  

  • 19. Trials in isolated systolic hypertension: an update.
    Waeber B
    Curr Cardiol Rep; 2003 Nov; 5(6):427-34. PubMed ID: 14558982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical appraisal of the JNC VI, WHO/ISH and BHS guidelines for essential hypertension.
    O'Brien E; Staessen JA
    Expert Opin Pharmacother; 2000 May; 1(4):675-82. PubMed ID: 11249509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.